Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat the analyst consensus estimate of $26.490 million by 9.87 percent. This is a 8.72 percent increase over sales of $26.771 million the same period last year.